H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $49 from $46 and keeps a Buy rating on the shares following the Q3 report. The firm sees the key value driver for the shares as sentiment on the commercial future for zanzalintinib across various tumor types.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $51 from $44 at TD Cowen
- Exelixis price target raised to $43 from $41 at Stifel
- Exelixis price target raised to $41 from $40 at Barclays
- Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
- Exelixis Reports Strong Q3 2025 Financial Results